Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16-positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Jessica Mcdermott, MD
Study ID
Protocol Number: 21-3833
More information available at ClinicalTrials.gov: NCT04398524
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers